Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 3Thoracic 1

Conditions

Anemia 2Renal Anemia 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 1492Cisplatin 1415Paclitaxel 1319Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1111Bevacizumab 1031Fluorouracil 895Doxorubicin 792Dexamethasone 748Rituximab 720Capecitabine 717Oxaliplatin 701pembrolizumab 680Etoposide 678Irinotecan 636Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 560Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 428Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interventional × continuous erythropoietin receptor activator × Clear all
NCT00717366 2017-09-08

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Hoffmann-La Roche

Phase 2 Completed
64 enrolled 15 charts 1 FDA
Classical hematology

Renal Anemia

NCT00327535 2016-08-11

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Hoffmann-La Roche

Phase 2 Completed
153 enrolled
Classical hematology

Anemia

NCT00072059 2013-07-18

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡